MA30175B1 - Ligands qui lient il-4 et/ou il-13 - Google Patents

Ligands qui lient il-4 et/ou il-13

Info

Publication number
MA30175B1
MA30175B1 MA31143A MA31143A MA30175B1 MA 30175 B1 MA30175 B1 MA 30175B1 MA 31143 A MA31143 A MA 31143A MA 31143 A MA31143 A MA 31143A MA 30175 B1 MA30175 B1 MA 30175B1
Authority
MA
Morocco
Prior art keywords
ligands
bind
interleukin
treatment
invention concerns
Prior art date
Application number
MA31143A
Other languages
English (en)
Inventor
Ian Tomlinson
Adriaan Allart Stoop
Armin Sepp
Silva Inusha De
Caroline J Dimech
Malgorzata Pupecka
Wildt Rudolf M T De
Philip D Drew
Steve Holmes
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of MA30175B1 publication Critical patent/MA30175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES LIGANDS QUI ONT UNE SPÉCIFICITÉ DE LIAISON POUR L¿INTERLEUKINE-4 (IL-4), L¿INTERLEUKINE-13 (IL-13) OU POUR IL-4 ET IL-13. SONT ÉGALEMENT INDIQUÉS DES PROCÉDÉS D¿UTILISATION DE CES LIGANDS. L¿UTILISATION DE CES LIGANDS POUR LE TRAITEMENT D¿UN ASTHME ALLERGIQUE EST EN PARTICULIER DÉCRITE.
MA31143A 2006-01-24 2008-07-25 Ligands qui lient il-4 et/ou il-13 MA30175B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76170806P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
MA30175B1 true MA30175B1 (fr) 2009-01-02

Family

ID=38028503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31143A MA30175B1 (fr) 2006-01-24 2008-07-25 Ligands qui lient il-4 et/ou il-13

Country Status (16)

Country Link
US (3) US20110159003A1 (fr)
EP (1) EP1976882A2 (fr)
JP (2) JP2009523460A (fr)
KR (1) KR20080098382A (fr)
CN (1) CN101578298A (fr)
AU (1) AU2007209202A1 (fr)
BR (1) BRPI0710572A2 (fr)
CA (1) CA2636854A1 (fr)
CR (1) CR10179A (fr)
EA (1) EA200801515A1 (fr)
IL (1) IL192572A0 (fr)
MA (1) MA30175B1 (fr)
NO (1) NO20082942L (fr)
TW (2) TW200740843A (fr)
WO (1) WO2007085815A2 (fr)
ZA (1) ZA200806202B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
WO2009138413A1 (fr) * 2008-05-15 2009-11-19 Domantis Limited Anticorps à domaine unique qui lient il-13
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
AU2007358569B2 (en) * 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2036980A1 (fr) * 2007-09-14 2009-03-18 Gruber, Jens Dérégulation de l'expression génétique à l'aide de particules semblables à un virus chargées d'acide nucléique
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
AU2017201008B2 (en) * 2007-10-15 2018-12-13 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
AU2008334605B2 (en) * 2007-12-13 2013-07-18 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2009089295A2 (fr) * 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps à domaine anti-vih et procédé de fabrication et d'utilisation de ceux-ci
CN112481367A (zh) * 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2010035012A1 (fr) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
EP2356149A2 (fr) * 2008-10-21 2011-08-17 Domantis Limited Ligands ayant une spécificité de liaison pour dc-sign
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
KR20110092328A (ko) * 2008-11-26 2011-08-17 글락소 그룹 리미티드 Ｉｌ-13에 결합하는 리간드
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
SG176203A1 (en) * 2009-05-28 2011-12-29 Glaxo Group Ltd Il-13 binding protein
ES2729422T3 (es) 2009-05-28 2019-11-04 Glaxo Group Ltd Proteínas de unión al antígeno
CA2768462A1 (fr) * 2009-07-16 2011-01-20 Glaxo Group Ltd. Domaines variables uniques de liaison anti-albumine serique ameliores
BR112012001977A2 (pt) * 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
EP2531523A1 (fr) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capables de se lier à la sérumalbumine, et composés, constructions, et polypeptides comprenant de tels peptides
PL2533761T3 (pl) * 2010-02-11 2019-09-30 Ablynx N.V. Sposoby i kompozycje do wytwarzania aerozoli
BR112012027863B1 (pt) 2010-04-30 2023-03-07 Janssen Biotech, Inc Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação
JP6062375B2 (ja) 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MY165090A (en) 2011-04-21 2018-02-28 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
PE20150643A1 (es) 2012-06-22 2015-05-29 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN106068125B (zh) * 2013-12-17 2021-08-31 Mhs克尔创新有限责任公司 治疗脂肪组织积聚的组合物和方法
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
KR102368450B1 (ko) * 2014-02-21 2022-02-28 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한 천식의 치료 또는 예방 방법
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
MX2016013372A (es) 2014-04-11 2017-01-26 Novartis Ag Metodos de tratar selectivamente el asma utilizando antagonistas de il-13.
AU2015329936A1 (en) 2014-10-10 2017-04-20 Ablynx N.V. Methods of treating RSV infections
KR102364212B1 (ko) 2014-10-10 2022-02-17 아블린쓰 엔.브이. 호흡기 질병들의 에어로졸 치료에 사용하기 위한 흡입 디바이스
EP3218412A1 (fr) 2014-11-14 2017-09-20 Sanofi Biotechnology Méthodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r
WO2016097313A1 (fr) 2014-12-19 2016-06-23 Ablynx N.V. Dimères de nano-anticorps liés à de la cystéine
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
JP6293829B2 (ja) * 2016-08-05 2018-03-14 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
WO2018099968A1 (fr) 2016-11-29 2018-06-07 Ablynx N.V. Traitement d'une infection par le virus respiratoire syncytial (vrs)
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech Inc domínios do tipo iii da fibronectina de ligação a cd8a
EP3554535A4 (fr) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à pd-l1
EP3554561B1 (fr) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
CN111526920A (zh) 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
CN108855003B (zh) * 2018-06-28 2021-01-05 南开大学 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
WO2020176815A2 (fr) * 2019-02-27 2020-09-03 Zhejiang Nanomab Technology Center Co. Ltd. Procédé à haut rendement basé sur une séquence générant des anticorps de camélidé pour couvrir de larges épitopes avec une haute résolution
EP4045061A4 (fr) 2019-10-14 2024-04-17 Aro Biotherapeutics Company Domaines de type iii de fibronectine de liaison à cd137
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4144758A4 (fr) 2020-04-22 2024-05-15 Mabwell Shanghai Bioscience Co Ltd Anticorps à domaine variable unique ciblant le ligand 1 humain de mort programmée (pd-l1) et dérivé de celui-ci
IL297950A (en) * 2020-05-06 2023-01-01 Dragonfly Therapeutics Inc Clec12a-targeting antibodies and their use
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2024038112A1 (fr) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Nanocorps anti-albumine améliorés et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2121078T3 (es) * 1992-02-19 1998-11-16 Schering Corp Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP1517921B1 (fr) * 2002-06-28 2006-06-07 Domantis Limited Ligands a specificite double et avec une demi-vie augmentee
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PT2805728T (pt) * 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
CA2554596A1 (fr) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006023460A2 (fr) * 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique

Also Published As

Publication number Publication date
TW200740843A (en) 2007-11-01
WO2007085815A3 (fr) 2007-11-15
TW200804593A (en) 2008-01-16
US20090060916A1 (en) 2009-03-05
IL192572A0 (en) 2009-02-11
WO2007085815A2 (fr) 2007-08-02
EA200801515A1 (ru) 2009-02-27
JP2009523459A (ja) 2009-06-25
US20110159003A1 (en) 2011-06-30
NO20082942L (no) 2008-10-15
CN101578298A (zh) 2009-11-11
EP1976882A2 (fr) 2008-10-08
CA2636854A1 (fr) 2007-08-02
JP2009523460A (ja) 2009-06-25
ZA200806202B (en) 2009-11-25
KR20080098382A (ko) 2008-11-07
US20120093830A1 (en) 2012-04-19
BRPI0710572A2 (pt) 2013-01-08
CR10179A (es) 2008-10-29
WO2007085815A8 (fr) 2008-07-31
AU2007209202A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
MA30175B1 (fr) Ligands qui lient il-4 et/ou il-13
SG147444A1 (en) Anti-ox40l antibodies
MA30021B1 (fr) Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation
WO2007120626A3 (fr) Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
WO2006003388A3 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
NO20083712L (no) Peptider som blokkerer bindingen av IGG til FCRN
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2006105304A3 (fr) Modulateurs lta4h de phenyle et pyridyle
ATE471032T1 (de) Verfahren und system zur echolöschung bei wenig verzögerung
IL244803A0 (en) Human anti-beta7 antibodies and their use
MA31918B1 (fr) Agents et épitopes de liaison à wise
TW200709817A (en) Platform antibody compositions
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MA31304B1 (fr) Molecules et procedes de modulation de proproteine convertase subtilisine/kexine de type 9 (pcsk9)
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX344592B (es) Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MX2008011874A (es) Composiciones estabilizadas de polipeptidos.
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA30872B1 (fr) Compositions d'inhibiteurs de la chk1.
NO20092743L (no) Antistoffer mot CD200R
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
HK1154904A1 (zh) 天然 抗體及其抑制劑
TW200730169A (en) Use of a β-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints